Excerpts

Survival analyses of our patient cohort showed that patients with CSCC had a better disease-free survival compared to patients with CAC, although the difference was at the limit of significance ( Figure S1 , p = 0.088). 3.4.

Regarding margin status, R0CRM− resection was achieved in 17 MP-positive cases (61.3%) and 15 MP-negative cases (88.2%), indicating a statistical trend ( p = 0.088). 3.4.

However, in the group with traditional MLD (control group), a significant decrease in the number of efferent lymphatic vessels was observed between the baseline and the post-intensive phase ( p = 0.026), as well as a borderline significant decrease between the baseline and 6 months of maintenance ( p = 0.089).

A possible trend towards a lower expression of PHD2 in stage II + III vs. stage I disease was observed ( p = 0.0890).

High FEN1 nuclear expression was also significantly associated with poor progression-free survival (PFS) ( p = 0.017) ( Figure 1 B) and was borderline non-significant with overall survival (OS) ( p = 0.089) ( Figure 1 C).

The hazard ratio for IL-3Rα-positive samples corresponded to 1.50 (CI = 95% 1.01–2.2; p = 0.04) and was near to significance after multivariate adjustment (hazard ratio = 2.01:0.89–4.89, p = 0.089).

The Gal-8 expression in the nucleus correlated negatively with the tumor grading and showed a trend towards a lower IRS in higher tumor grading ( p = 0.089).

Results: The results of Kaplan–Meier survival analysis revealed that the MutS homolog 2 (MSH2) rs3732183 polymorphism showed a borderline significant association with DFS (log-rank p = 0.089).

Furthermore, tumor mutational burden (sum of somatic point mutations) showed a trend towards decreased PFS (HR 1.9, p = 0.089), and chromosomal instability (CIN) was associated with shorter PFS (HR 2.3, p = 0.023), independent of HPV status.

Patients harboring a KRAS mutation showed a statistically significant lower OR for platinum sensitive disease (OR = 0.72 [95% CI, 0.56–0.92], p = 0.010), and patients with CCNE1 amplifications showed a trend for a statistically significant lower OR for platinum sensitive disease (OR = 0.84 [95% CI, 0.68–1.03], p = 0.089).

Gender remained significant for EFS (HR: 1.62, p = 0.028), with females at higher risk, and approached significance for OS (HR: 1.52, p = 0.089).

A tendency toward significance was found in cases with high genomic instability and the occurrence of CTH ( p = 0.0894).

Lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) presented moderately significant p -values in scores for macrophages ( p = 0.08976), Tgammadelta ( p = 0.08334), and NK cells ( p = 0.1221).

after ICI initiation, although we observed a near-significant trend for cancer type ( p = 0.09), with NSCLC accounting for more than 60% of cases receiving antibiotics post-ICI initiation ( Supplementary Table S3 ). 3.2.

mismatched donor including haplo and MMUD 9/10), the difference in OS was of borderline significance in favor of 10/10 matched donors ( p = 0.09).

Patients with brain metastasis ( n = 13) showed a marginally significant difference in the median PFS1 compared to patients without brain metastasis ( n = 27) (13.1 months vs. 35.8 months, p = 0.09) ( Figure S1 ). 3.3.

The best cutoff was set at 2.0 mg/Land resulted in a marginally significant prediction, with 10-year FFP rates of 74% versus 64% ( p = 0.09, Figure 1 F).

The RT group showed a trend to be diagnosed more often with a stenosis of the carotid arteries ( p = 0.09) and second carcinomas ( p = 0.17), esophageal stenosis ( p = 0.18) and osteoradionecrosis (ORN) ( p = 0.07).

By the end of the study period, 21/22 (95.4%) patients in the suprasellar group survived, versus 12/16 (75%) in the bifocal and 4/4 (100%) in the BG-GCT groups, a trend toward significance ( p = 0.09) ( Figure 9 B).

Changes in CTC-cluster counts from baseline to follow up were not able to predict patient outcome in terms of PFS and OS, however, for patients in the high risk group, there was a clear trend towards a shorter OS ( P log-rank = 0.07) and increased risk of death, with a HR of 2.96 (95% CI 0.83–10.5; p = 0.09) ( Figure 4 , Table 4 ). 2.6.

Women who were initially treated with SCS at the time of recurrence showed a trend towards a longer median survival than those who underwent chemotherapy followed by SCS (83.3 versus 33.2 months, p = 0.09). 3.2.

The plot for overall survival shows a trend toward significance for the difference between the groups of patients with m2Ddr above and below the cutoff (log-rank test, p = 0.090; Figure 3 ). 4.

We identified a nearly statistically significant (adjusted p = 0.09) cut point at approximately the 40th quantile of the distribution of the full signature (Ridge), separating patients with good or bad prognosis, and similarly for the subset signature (Boot Lasso), with a cut point at approximately the 60% quantile of the distribution of the signature ( Supplementary Figure S14A,B ).

BRAF mutation status significantly associated with RAI-R tumors ( p = 0.010, Table 2 ) and showed only a positive trend of statistical association with disease recurrence/persistence ( p = 0.090), as previously shown [ 1 ].

In addition, high mRNA levels of KIF4A showed a trend towards a poorer progression-free survival ( p = 0.09) and upon knockdown, reduced the proliferation of Ben-Men-1 cells.